TGFB1 and leukemia: Concerning the first, leukemia is commonly characterized by the development of a TGF-β resistance mechanism which consists of the downregulation of TGF-β or its receptors, or by the mutation/deletion of the intracellular mediators of TGF-β signaling pathway, like the SMAD proteins.